Has this broker made the right call on Woolworths Limited?

Woolworths Limited (ASX:WOW) is facing pressure from many angles according to broker Morgan Stanley.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) charging 1.6% higher today as investors cheer on policy makers within the European Union who are expected to shortly approve further monetary stimulus measures, it is perhaps not surprising that shareholders in Woolworths Limited (ASX: WOW) are enjoying a rally in the retail giant's share price.

What is perhaps surprising is the size of the gains (the stock is up 2.7%) given the negative news reports which have featured in the past few days.

On Tuesday, the Australian Financial Review ran a story which highlighted 10 challenges the supermarket operator faces according to analysis by investment bank Morgan Stanley.

Amongst the concerns highlighted were:

  • A slowing consumer cycle
  • The increasingly watchful eye of the Australian Consumer and Competition Commission (ACCC) on the sector
  • Decreasing returns on equity (ROE)

Then on Wednesday the Fairfax press reported on the stellar performance of competitor Aldi Australia. In 2014 the German-headquartered group reported a 13% increase in sales which was approximately three times the growth rate of both Woolworths and Coles, which is owned by Wesfarmers Ltd (ASX: WES)!

Although this growth is off a much lower base – Aldi had sales of $6 billion which is well below second placed Coles with $29 billion – the view of some market watchers is that Aldi will continue to grow its market share as it expands into the new regions of Western Australia and South Australia.

Buy, hold, or sell?

Despite today's gains, Woolworths' share price is still down 9.6% over the past 12 months. The stock closed Wednesday's trade at $30.87, which is above the target price of $27 that Morgan Stanley has on the stock. If the broker's analysis and valuation is accurate then some investors will no doubt prefer to wait for a lower entry point.

Conversely, with the stock trading on a forecast price-to-earnings ratio of 15.2x and fully franked yield of 4.7%, long term, conservative investors may find today's pricing quite appealing given the blue-chip status of the stock.

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned.  

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »